Blueberries Provides Corporate Update, Extends Maturity Date Of Convertible Debentures

Blueberries Medical Corp. (OTCQB: BBRRF) (CSE:BBM) (FRA:1OA) has achieved several CBD and non-psychoactive derivatives shipments to customers in Argentina, and up to date has exported a total of more than 60 kg to 6 different buyers.

Quality validation processes with larger pharmaceutical and cosmetics companies in this country are running positively, and the company estimates annual sales above $2.5 million in 2023. It is also expected that in late Q3 2022, Blueberries initiates the delivery of multiple high THC formulations locally and internationally, starting with Brazil as the first country to export psychoactive formulations. Both Argentina and Brazil are then expected to become the two largest destinations of the company products in next quarters.

Effective June 30th, the Colombian Ministry of Justice granted Blueberries the psychoactive and non-psychoactive flower export licenses. Also, the company has signed an agreement with YVY Life Sciences, a Uruguayan company specialized in quality dry flower production to mutually exploit the Blueberries´ growing facilities. YVY Life Sciences will upgrade and operate this facility for the next 3 years, with the intention …

Full story available on Benzinga.com

Blueberries Provides Corporate Update, Extends Maturity Date Of Convertible Debentures on Benzinga